AnteoTech Ltd (ASX: ADO) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

AnteoTech Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $32.70 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 2.97 billion
Earnings per share -0.002
Dividend per share N/A
Year To Date Return -50.00%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

AnteoTech Ltd (ASX: ADO)
Latest News

Sonic Healthcare share price represented by man receiveing nasal swab from medical professional
Share Fallers

AnteoTech (ASX:ADO) share price sinks 12% lower following COVID-19 test update

The AnteoTech Ltd (ASX:ADO) share price is sinking lower on Wednesday following the release of an update on its COVID-19…

Read more »

bar graph with man jumping over low number representing dip in asx shares
Share Market News

These fund managers are buying the dip, should you?

Fund managers have been snapping up internet and software shares. Is this the right time to for you to buy…

Read more »

pair of gloved hands holding cotton swab and test tube towards car window representing Anteotech share price
Share Market News

Anteotech (ASX:ADO) share price rockets 19% on COVID test announcement

The Anteotech share price is up nearly 19% today following the company's ASX announcement on progress with its COVID-19 rapid…

Read more »

⏸️ Investing

4 ASX stocks savaged by the market today

S&P/ASX 200 slides 0.5% to start the week, but these four stocks were hammered

Read more »

a woman
⏸️ Investing

4 ASX stocks powering higher today

Sirtex Medical Limited (ASX:SRX) and Fatfish Internet Group Ltd (ASX:FFG) have seen some strong buyer support today.

Read more »

a woman
⏸️ Investing

Could these 2 health sector stocks be the Sirtex Medical Limited of tomorrow?

You probably don’t know these micro-caps but they may deserve a place on your watchlist.

Read more »

a woman
⏸️ Investing

7 speculative stocks deserving your attention

Sometimes, it pays to give luck a chance...

Read more »

a woman
⏸️ Investing

7 stellar stocks still guided by their founders

Exceptional individuals make shareholders millions as they guide their companies to grow: are you missing out? Seek and Vocus are…

Read more »

a woman
⏸️ Investing

3 clever companies for any healthy share portfolio

CSL, Azure Healthcare and Anteo Diagnostics are all in the business of commercialising the inventions of clever scientists. Better yet,…

Read more »

a woman
⏸️ Investing

My top 3 speculative stocks for 2014 revisited

The risks and rewards of speculative investments can be quite a distraction from the search for a great business at…

Read more »

ADO ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About AnteoTech Ltd

AnteoTech Ltd is a biotechnology company engaged in the development of specialty products and services and end-user diagnostic products focused on the Battery and Life Science diagnostics markets. Its key areas are the Energy and Life Science Division. The company is developing four products named AnteoX, Ultranode, AnteoBind NXT, and AnteoBind these products are used in the energy, diagnostic, and medical device markets. The company currently has a single segment which is the development of the AnteoTech IP.

ADO Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
19 Mar 2026 $0.01 $0.00 0.00% 3,727,653 $0.01 $0.01 $0.01
18 Mar 2026 $0.01 $0.00 0.00% 1,176,889 $0.01 $0.01 $0.01
17 Mar 2026 $0.01 $0.00 0.00% 425,295 $0.01 $0.01 $0.01
16 Mar 2026 $0.01 $0.00 0.00% 4,046,728 $0.01 $0.01 $0.01
13 Mar 2026 $0.01 $0.00 0.00% 2,270,473 $0.01 $0.01 $0.01
12 Mar 2026 $0.01 $0.00 0.00% 9,782,906 $0.01 $0.01 $0.01
11 Mar 2026 $0.01 $0.00 0.00% 1,929,996 $0.01 $0.01 $0.01
10 Mar 2026 $0.01 $0.00 0.00% 278,253 $0.01 $0.01 $0.01
09 Mar 2026 $0.01 $0.00 0.00% 1,316,482 $0.01 $0.01 $0.01
06 Mar 2026 $0.01 $0.00 0.00% 5,361,530 $0.01 $0.01 $0.01
05 Mar 2026 $0.01 $0.00 0.00% 845,705 $0.01 $0.01 $0.01
04 Mar 2026 $0.01 $0.00 0.00% 1,591,517 $0.01 $0.01 $0.01
03 Mar 2026 $0.01 $0.00 0.00% 125,250 $0.01 $0.01 $0.01
02 Mar 2026 $0.01 $0.00 0.00% 4,671,393 $0.01 $0.01 $0.01
27 Feb 2026 $0.01 $0.00 0.00% 6,670,180 $0.01 $0.01 $0.01
26 Feb 2026 $0.01 $0.00 0.00% 129,299 $0.01 $0.01 $0.01
25 Feb 2026 $0.01 $0.00 0.00% 153,692 $0.01 $0.01 $0.01
24 Feb 2026 $0.01 $0.00 0.00% 206,974 $0.01 $0.01 $0.01
23 Feb 2026 $0.01 $0.00 0.00% 1,462,357 $0.01 $0.01 $0.01
20 Feb 2026 $0.01 $0.00 0.00% 4,135,747 $0.01 $0.01 $0.01
19 Feb 2026 $0.01 $0.00 0.00% 1,418,594 $0.01 $0.01 $0.01
18 Feb 2026 $0.01 $0.00 0.00% 1,740,159 $0.01 $0.01 $0.01
17 Feb 2026 $0.01 $0.00 0.00% 293,429 $0.01 $0.01 $0.01

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
26 Nov 2025 Geoffrey Cumming Expiry 3,500,000 $66,500
Options expired.
26 Nov 2025 Geoffrey Cumming Issued 5,000,000 $95,000
Issue of options.
26 Nov 2025 Glenda McLoughlin Issued 7,500,000 $142,500
Issue of options.
26 Nov 2025 Glenda McLoughlin Expiry 5,000,000 $95,000
Options expired.
26 Nov 2025 Merrill Gray Issued 30,000,000 $570,000
Issue of options.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Dr Geoffrey James Cumming Non-Executive Director Apr 2009
Dr Cumming has over 20 years of experience in the healthcare and biotechnology market. His roles have progressed from pure research to sales and marketing roles through to Managing Director level and on the Board. Previously Managing Director of Roche Diagnostic Systems - Oceania Regional Centre. He was also Managing Director and CEO of Biosceptre Ltd, an Australian based biotechnology company commercializing a range of products in cancer diagnosis and treatment. During his tenure he was responsible for doing research from Sydney University through to product registration. This involved capital raising, managing Intellectual Property, investor relations and forging links with relevant international partners. He is the Chair of the Risk Committee.
Ms Glenda McLoughlin Non-Executive Director Sep 2021
Ms McLoughlin has commercial experience as a senior investment banker, commercial advisor and founder. She has over 20 years of experience on listed company boards. In her executive career she held senior executive roles at leading financial institutions Morgan Stanley, Credit Suisse and Barclays Capital where she led the Energy and Infrastructure Group in Australia. In addition to her work in the energy sector, Ms McLoughlin has experience in medical diagnostics, telecommunications, information technology, media, transport and financial services sectors. She is a member of the and Risk Committee.
Mr Richard Shubrick Martin Non-Executive Director Sep 2005
Mr Martin holds a Bachelor of Business. He practised as a Chartered Accountant for 16 years, 11 as a partner in a medium sized Sydney practice. Mr Martin has been involved with the Company since it was founded by Dr Maeji. He has considerable experience both operationally and advising corporate entities, his work has included complex business structuring and financing, the establishment of international hotels from conception, public listing of companies, management of foreign currency exposure, establishing and operating start up technology companies and the negotiation and implementation on the purchase and sale of enterprises.
Ms Merrill Christina Gray Non-Executive Director Jan 2025
Ms Gray is an experienced executive and Board member, with a 30-year career spanning a range of critical minerals, renewables and energy businesses. Ms Gray brings experience from the European Union and specifically with German automotive sector with Original Equipment Manufacturers (OEMs) in relation to the management of their battery materials supply chains. Ms Gray has held a range of executive business and technology development roles in Australia and globally. Her executive career has included accessing and developing new markets in Lithium-ion Battery (LiB) cathode and anode materials, LiB recycling, large scale renewable energy generation project development as well as establishing synfuels and waste to energy businesses. During this time, she spent long periods in Germany and worked with Mercedes-Benz, Primobius's first customer, amongst other European OEM's. She is a Member of the Risk Committee.
Mr Scott Waddell Company SecretaryInterim CFO Feb 2026
-
Scott Waddell Company SecretaryInterim CFO
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Marcolongo Nominees Pty Ltd 57,505,701 2.10%
First Cape Management Pty Ltd 55,195,509 2.00%
Addison Lake Quality Hire Pty Limited 38,844,879 1.40%
Sisters Palm Beach Pty Ltd 33,920,000 1.20%
AWO & CAO Investments Pty Ltd 31,200,000 1.10%
Mr Claus Kurt Dzalakowski 30,000,000 1.10%
Mr Claus Kurt Dzalakowski & Mrs Michelle Gay Dzalakowski 27,360,000 1.00%
Bond Street Custodians Limited 27,267,749 1.00%
Mr Peter Frederick Kemmis 27,040,676 1.00%
Bond Street Custodians Limited i 25,100,000 0.90%
Mr Anthony William Olding & Mrs Caroline Anne Olding 24,900,000 0.90%
Bnp Paribas Nominees Pty Ltd 23,925,035 0.90%
Marcolongo Nominees Pty Ltd i 23,356,544 0.90%
Computer Visions Pty Ltd 22,132,994 0.80%
Mcrae Superannuation Pty Ltd 22,125,000 0.80%
Terry & Linden Deavin Super Pty Ltd 21,150,212 0.80%
Mr Philip Michael Deavin & Mrs Chimene Maree Deavin 20,162,769 0.80%
Mr Antonio Di Lalla 19,986,924 0.70%
Mr David John Walls 17,000,000 0.60%
Mr Richard Shubrick Martin & Mrs Fiona Diana Martin 16,862,514 0.89%

Profile

since

Note